Brind.
  1. Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

Guardant Health announced on July 15, 2025, that its test was being used in the NCI's Vanguard Study, with data presented at ASCO in Chicago and FDA review initiated for IDE.

2 reports, 2 independent Updated Jul 3
Gone quiet
Reports
2
Developments
1
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Guardant Health announced on July 15, 2025, that its test was being used in the NCI's Vanguard Study, with data presented at ASCO in Chicago and FDA review initiated for IDE.

Who's involved

What this event is mainly about
Guardant HealthFDANational Cancer Institute

Keep exploring

Part of

Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines. All 3 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • thehindu.com
  • Business WireFirst Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test Study addressing feasibility of using multi-cancer detection tests